Literature DB >> 18651121

[Prostate cancer research. Biomarkers as promising options for optimized diagnosis and treatment].

J Ellinger1, A von Rücker, N Wernert, R Büttner, P J Bastian, S C Müller.   

Abstract

A better understanding of signal transduction and gene regulation during prostate carcinogenesis will allow the development of novel diagnostic and prognostic biomarkers and a better prediction of the individual course of prostate cancer disease. It will also enhance the design and development of specific small molecular components aiming for specific therapies. The research groups in Bonn succeeded in the competition for an endowed professorship supported by the Rudolf Becker Stiftung (German Science Endowment Fund) settled in the"Centrum für integrierte Onkologie" funded by the German Cancer Aid. This should be the perfect breeding ground for future research in the field of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18651121     DOI： 10.1007/s00120-008-1833-z

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  19 in total

1.  The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus.

Authors:  Judith M Müller; Eric Metzger; Holger Greschik; Anja-Katrin Bosserhoff; Luka Mercep; Reinhard Buettner; Roland Schüle
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

2.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

3.  Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts.

Authors:  Jens Claus Hahne; Tanja Fuchs; Haddouti El Mustapha; Ali Fuat Okuducu; Jean Christophe Bories; Nicolas Wernert
Journal:  Int J Mol Med       Date:  2006-07       Impact factor: 4.101

4.  Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.

Authors:  Patrick J Bastian; Jörg Ellinger; Axel Wellmann; Nicolas Wernert; Lukas C Heukamp; Stefan C Müller; Alexander von Ruecker
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

5.  Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth.

Authors:  Jens Claus Hahne; Ali Fuat Okuducu; Annette Kaminski; Alexandra Florin; Fabrice Soncin; Nicolas Wernert
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

6.  GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?

Authors:  P J Bastian; J Ellinger; D Schmidt; N Wernert; A Wellmann; S C Müller; A von Rücker
Journal:  Eur J Med Res       Date:  2004-11-29       Impact factor: 2.175

7.  Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.

Authors:  Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Xiaohui Lin; Craig G Rogers; Leslie A Mangold; Bruce Trock; Mario Eisenberger; Alan W Partin; William G Nelson
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

8.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.

Authors:  Eric Metzger; Melanie Wissmann; Na Yin; Judith M Müller; Robert Schneider; Antoine H F M Peters; Thomas Günther; Reinhard Buettner; Roland Schüle
Journal:  Nature       Date:  2005-08-03       Impact factor: 49.962

9.  Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.

Authors:  Jörg Ellinger; Stefan C Müller; Nicolas Wernert; Alexander von Ruecker; Patrick J Bastian
Journal:  BJU Int       Date:  2008-04-11       Impact factor: 5.588

10.  Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer.

Authors:  A Hügel; N Wernert
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.